TH177127A - Stabilized insulin glulisine formulation - Google Patents
Stabilized insulin glulisine formulationInfo
- Publication number
- TH177127A TH177127A TH1601002253A TH1601002253A TH177127A TH 177127 A TH177127 A TH 177127A TH 1601002253 A TH1601002253 A TH 1601002253A TH 1601002253 A TH1601002253 A TH 1601002253A TH 177127 A TH177127 A TH 177127A
- Authority
- TH
- Thailand
- Prior art keywords
- formulation
- insulin glulisine
- stabilized insulin
- glulisine
- water
- Prior art date
Links
- RCHHVVGSTHAVPF-ZPHPLDECSA-N Apidra Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CNC=N1 RCHHVVGSTHAVPF-ZPHPLDECSA-N 0.000 title claims 2
- 229960000696 insulin glulisine Drugs 0.000 title claims 2
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 2
- 229940079593 drugs Drugs 0.000 claims abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
Abstract
สิทธิบัตรยา Drug patent
Claims (2)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH177127A true TH177127A (en) | 2018-06-21 |
| TH1601002253A TH1601002253A (en) | 2018-06-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17044282A (en) | Insulin glargine / lixisenatide fixed ratio formulation | |
| TH177127A (en) | Stabilized insulin glulisine formulation | |
| AR103188A1 (en) | INJECTABLE PARACETAMOL FORMULATIONS | |
| TH1601004234A (en) | Pharmaceutical constituents containing IgM | |
| TH169430A (en) | Pharmaceutical components against chronic bacterial infection. | |
| TH1701002032A (en) | The use of neridronic acid or its salts for the treatment of osteomyelitis. | |
| TH1501005024A (en) | Pharmaceutical constituents for the treatment of fungal infections. | |
| TH1701002548A (en) | Long-acting pharmaceutical constituents for hepatitis C | |
| TH1701004077A (en) | Active substance for improving early insulin secretion capacity. | |
| TH180207A (en) | Improved stability of glucagon derivatives (GLUCAGON DERIVATIVES). | |
| TH1601000693A (en) | Early-release dosage form for JAK1 inhibitors. | |
| TH151384A (en) | Pharmaceutical components containing drugs with low water solubility. | |
| TH1701005228A (en) | Kv1.3 inhibitors and their medical applications | |
| TH1701003406A (en) | Pharmaceutical formulation of tropomieosin-related kinase inhibitors (TRK). | |
| TH1701001067A (en) | Pharmaceutical components and therapeutic combinations containing substances Inhibits cholesterol-transmitted proteins and HMG CoA reductase inhibitors. | |
| TH1701007223A (en) | Oral delivery system for bioactive substances | |
| TH168864A (en) | Fixed ratio formulation of insulin glargene / lixisinatide. | |
| TH158830A (en) | Pharmaceutical constituents containing antibodies against PCSK9. | |
| TH1701007724A (en) | ||
| TH1501005514A (en) | Biologically active molecules, their conjugates, and therapeutic use (Biologically Active Molecules, Conjugates Thereof, and Therapeutic Uses) | |
| TH1701002664A (en) | Therapeutic combination for the treatment of drug-resistant bacterial infections. | |
| TH1701001069A (en) | Tetrahydro-naphthalene derivatives that inhibit MCL-1 protein. | |
| TH1701005921A (en) | Substances used to treat dry eye syndrome Which includes the nandrolone or esters of this Or methinolone, or esters of this As an active ingredient | |
| TH181268A (en) | Macrosyclic RIP2 Kinase | |
| TH1701006519A (en) | A solid form of a compound in which modulated kinase. |